CROX vs HLI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CROX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CROX and HLI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CROX and HLI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Crocs, Inc. designs and sells casual footwear under two brands. The Crocs Brand centers on its signature molded clog made from a proprietary closed-cell resin the company calls Croslite, extended through sandals, sneakers, and the Jibbitz charms that let buyers personalize their shoes. In 2022 Crocs acquired HEYDUDE, a lightweight casual-shoe brand, to add a second growth engine. The company sells through wholesale partners and a growing direct-to-consumer channel that includes its own websites and stores, and it markets heavily through collaborations and celebrity tie-ins. Crocs is known for operating margins well above most footwear peers (about 24% on a trailing basis, with gross margin near 57%), driven by a simple core product, strong pricing, and relatively low marketing spend versus sales.

Full CROX guide

Houlihan Lokey, Inc. (NYSE: HLI) is an independent, advisory-focused investment bank founded in 1972 and headquartered in Los Angeles. It advises corporations, private equity sponsors, and governments across three segments: Corporate Finance (M&A and capital-raising, the largest slice at roughly two-thirds of revenue), Financial Restructuring (out-of-court workouts and bankruptcy advisory, where it is a global market leader by deal volume), and Financial and Valuation Advisory (fairness opinions, portfolio valuation, and financial consulting). Unlike bulge-bracket banks, Houlihan Lokey does not trade for its own account or make large loans, so its revenue is almost entirely advisory fees.

Full HLI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CROX drivers: High-margin core Crocs Brand; Cash generation and share buybacks.
• HLI drivers: Restructuring ballast; M&A and capital-markets recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is that Crocs depends heavily on one iconic product, so a shift in fashion or a fading of the clog trend could hurt demand quickly, and single-product concentration makes the stock sensitive to sentiment about the brand's staying power. For HLI, advisory revenue is inherently lumpy and tied to deal completions, so a prolonged M&A slowdown or credit freeze can pressure results even with the restructuring hedge; the two most recent quarters both missed EPS estimates, and the June 2026 quarter's $1.35 was about 18% below consensus.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CROX if you believe its drivers more; HLI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CROX and HLI guides.

CROX. Even after a roughly 44% gain in 2026, Crocs trades near 11 times trailing and 8 times forward earnings, cheap for a business with mid-20s operating margins, because the market still questions how long single-product profitability lasts and how much HEYDUDE will cost. Analysts' mean target is about $138.75 across 12 covering firms. The October 29, 2026 Q3 report (consensus ~$1.0 billion revenue, $3.30 EPS) will show whether the second-quarter return to growth holds.

HLI. At roughly $130 per share in mid-October 2026, HLI trades near a market cap of about $9.1 billion, with a trailing P/E around 22x and a forward multiple near 15x on expected EPS of about $8.63, a discount to the premium the stock has often held. The gap between those two multiples reflects a bet that deal fees recover after a soft first half of fiscal 2027. The nine covering analysts carry a mean target near $155 and a buy rating, and the fiscal second-quarter report on October 28, 2026 is the next test.

Headline figures (approximate, October 2026): CROX shows revenue (ttm) ~$4.05 billion; Q2 2026 ~$1.18 billion, up ~2.6% year over year, margins (ttm) Gross ~57%, operating ~24%, net ~15%, net income / eps (ttm) ~$593 million; trailing EPS ~$11.41, p/e (trailing / forward) ~10.9x / ~8.3x; HLI shows revenue (ttm) ~$2.52B (June 2026 quarter ~$511M, down ~15.5% YoY), revenue (fy2026, ended mar 2026) ~$2.62B (up ~10%), net income (ttm) ~$406M (~16% net margin), eps (latest quarter) ~$1.35 vs ~$1.64 expected.

CROX and HLI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CROX and HLI exposure against your real portfolio. It is not an investment adviser.